Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

PeptiGrowth Inc. Launches Novel Synthetic KGF Alternative Peptide (FGFR2b Agonist)

PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called "KGF alternative- peptide (FGFR2b agonist)" which is functionally equivalent to recombinant keratinocyte...

Hanmi Pharmaceutical Launches 'Aditams' in Mexico, Expanding into Latin America

Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is entering the Mexican market under the local brand name "Aditams." Hanmi...

ELIQUENT Life Sciences Acquires Truliant Consulting, Expanding Pharmacovigilance Platform

ELIQUENT Life Sciences (ELIQUENT), a global regulatory, quality, and safety consulting firm, today announced the acquisition of Truliant Consulting (Truliant), a leading pharmacovigilance, risk management, and regulatory compliance advisory firm....

Pint Pharma secures ANVISA approval for BESREMi® to treat Polycythemia Vera

Pint Pharma and PharmaEssentia announced that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia Vera (PV). Polycythemia Vera (PV) is a rare, chronic,...

Secretome Therapeutics' STM-01, a neonatal cardiac progenitor cell therapy for HFpEF, receives FDA Fast Track designation

Secretome Therapeutics, a pioneering company in the field of regenerative medicine, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the company’s neonatal cardiac progenitor cell (nCPC)...

Developing innovative production technology for the commercialization of 3D cell products, PHC and Cyfuse collaborate

PHC Corporation a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. announce the successful development of a new production technology(*1) for the commercialization of...

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

Actinium Pharmaceuticals, Inc. a pioneer in the development of targeted radiotherapies, announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M in patients with relapsed/refractory acute...

Key Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial Reported by Blue Earth Therapeutics

Blue Earth Therapeutics today announced further promising developments for its radiohybrid lutetium labelled, PSMA targeted, investigational radioligand therapy. Radiation dosimetry and pharmacokinetic data from the 13 metastatic castrate...

Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment.

Fzata, Inc. announces the execution of a clinical trial agreement with the National Institutes of Health (NIH) to sponsor a Phase 1 clinical trial of FZ002 for C. difficile treatment. Oral FZ002 is a live yeast genetically modified to express a...

Viking Therapeutics and CordenPharma Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables, and Oral Formulations

CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO) specializing in the supply of peptide APIs and peptide-based therapeutic finished dosage drug products, is pleased to announce the signing of a strategic partnership...

Kenox Pharmaceuticals announces a strategic collaboration with Lactiga to advance immunotherapy targeting mucosal areas

Kenox Pharmaceuticals Inc. and Lactiga US, Inc. are pleased to announce a strategic collaboration to advance the development of novel, groundbreaking, mucosal-targeted Secretory IgA (sIgA) therapies for immunodeficient patients. This partnership...

MedaSystems secures additional seed financing to advance its AI-driven workflow platform, expanding access and supporting investigator-initiated studies

MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator-Initiated Studies (IIS), announced additional funding from existing investors, Debiopharm Innovation Fund, Nina Capital, and Young Sohn, a co-founder of Veeva...

Dr. Scott Grady Makes Thyroid RFA More Accessible in Oregon

Dr. Scott Grady, an endocrinologist at Portland Diabetes & Endocrinology Center (PDEC), is making Thyroid Radiofrequency Ablation (RFA) more accessible to Oregon patients seeking a non-surgical alternative for benign thyroid nodules. Since 2022,...

TOOsonix Partners with MikronMed to Introduce Innovative Dermatological Therapy in the Nordic Region

TOOsonix A/S, a leader in high-intensity focused ultrasound technology for dermatology, has partnered with MikronMed AB, a top distributor of medical equipment in the Nordic region. The collaboration will bring TOOsonix innovative MDR CE marked...

Cellino Launches the U.S.’s First Nebula-Powered iPSC Foundry for Scalable Autologous Biomanufacturing

Cellino announced its collaboration with Mass General Brigham’s Gene and Cell Therapy Institute (GCTI) to launch the world’s first hospital-based autologous induced pluripotent stem cell (iPSC) Foundry. Powered by Cellino’s AI-driven Nebula...

Regemat 3D to Distribute VitroInk® Bioinks in Europe: A Strategic Move for Advanced Bioprinting Solutions

TheWell Bioscience, a leading biotech company specializing in xeno-free biofunctional hydrogels and bioinks, is pleased to announce the non-exclusive distribution of its products through REGEMAT 3D, a leading biotech company specializing in the...

A convenient and cost-effective way to treat sickle cell disease may be offered by Vascarta's patented transdermal drug candidate

An article in the Proceedings of the National Academy of Sciences (PNAS) Nexus journal* by Goel et al. describes studies in which humanized sickle cell mice topically treated with Vascarta's transdermal curcumin gel formulation ("VAS-101")...

Fosun Pharma deeply embraces AI, with its self-developed PharmAID Decision Intelligence Platform boosting efficient innovation

Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the...

Fresenius Kabi Launches Calcitonin Salmon Injection, USP Synthetic

Fresenius Kabi, an operating company of Fresenius, announced today it has introduced Calcitonin Salmon Injection, USP Synthetic, a calcium regulator, for the treatment of symptomatic Paget’s disease of the bone and hypercalcemia. The drug is also...

Marius Pharmaceuticals Expands Men's Health Solutions by Announcing the Availability of KYZATREX® (testosterone undecanoate) CIII Capsules Through Thrive

Marius Pharmaceuticals is pleased to announce that Thrive, a leading provider of personalized healthcare solutions and a trusted partner of O2 Fitness, now offers KYZATREX® (testosterone undecanoate) CIII capsules to its patients nationwide....